arrow
V

Văn Hùng Nguyễn

a vhn consulting inc.
H指数:23
被引数:2,190

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19-related Hospitalizations and Medical Encounters Among Adults in the United States

含有2023-2024 Omicron XBB.1.5的mRNA新型冠状病毒肺炎疫苗 (mRNA-1273.815) 在预防美国成年人COVID-19-related住院和医疗接触中的有效性

2024-11-262
OAAI
Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States

双价 (原始/Omicron BA.4/BA.5) mRNA新型冠状病毒肺炎疫苗mRNA-1273.222和BNT162b2双价在美国患有基础疾病的成年人中的比较有效性

2024-09-272
OAAI
Relative Effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines and Homologous Boosting in Preventing COVID-19 in Adults in the US

BNT162b2,mRNA-1273和ad26.cov2.s疫苗和同源加强预防美国成人新型冠状病毒肺炎的相对有效性

2023-05-2515
OAAI
Correction to: Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy
2022-11-250
OA
Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome (vol 50, pg 1650, 2018)
2018-11-142
OAAI